The reason for a long survival rate of functional blebs in PG eyes after filtration surgery
is still unknown.
While descriptions of surgical management in this text are centred on more common types of glaucoma, such as paediatric, angle closure and laser approaches to management, not to mention how to deal with concurrent cataract extraction in glaucoma filtration surgery
, the text does not shy away from discussing more modern techniques such as the minute stent procedure, which aims to increase aqueous outflow at Schlemm's canal in order to reduce intraocular pressure, to cyclodestructive approaches which are reserved for patients who are unresponsive to even surgical methods of glaucoma management.
INDICATIONS: Glaucoma drainage device implantation is usually reserved for cases with refractory glaucoma, or those unlikely to respond successfully to a conventional filtration surgery.
Contact lens wearers who need glaucoma filtration surgery.
EX-PRESS GLAUCOMA FILTRATION DEVICE4: The Ex PRESS shunt is on the forefront of evolution towards smaller incision glaucoma filtration surgery.
Guarded filtration surgery
(GFS) using Ahmed, Molteno and Baervaldt implants has been found to be very effective in obtaining control in aniridic glaucoma with success rates ranging from 66% to 100%.
a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery.
PRM-151 was granted Orphan Medicinal Product Designation by the European Commission in September 2009 for use in the prevention of scarring post glaucoma filtration surgery.
The orphan medicinal product designation for PRM-151 reflects the therapeutic potential of PRM-151 to prevent scarring post glaucoma filtration surgery
and the lack of approved alternative therapies for this serious surgical complication," said Dominick Colangelo, Chief Executive Officer of Promedior.
Food and Drug Administration (FDA) has granted premarket approval (PMA) of Healon D([R]) viscoelastic, a clear dispersive ophthalmic viscosurgical device (OVD) for use as a surgical aid in cataract extraction, intraocular lens (IOL) implantation, corneal transplant, and glaucoma filtration surgery
The most immediate application of the paclitaxel implant will be for patients undergoing glaucoma filtration surgery